Vera, K., Djafari, L., Faivre, S., Djazouli, K., Osorio, M., ...
Background: Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150–200 mg/m2/day on days 1–5 every 4 weeks. In this study, a new alternative...